The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment: Two Randomized Controlled Trials
Open accessAbstract
CONTEXT: Patients with chronic disabling gout refractory to conventional urate-lowering therapy need timely treatment to control disease manifestations related to tissue urate crystal deposition. Pegloticase, monomethoxypoly(ethylene glycol)-conjugated mammalian recombinant uricase, was developed to fulfill this need. OBJECTIVE: To assess the efficacy and tolerability of pegloticase in managing refractory chronic gout. DESIGN, SETTING, AND PATIENTS: Two replicate, randomized, double-blind, placebo-controlled trials (C0405 and C0406) were conducted between June 2006 and October 2007 at 56 rheumatology practices in the United States, Canada, and Mexico in patients with severe gout, allopurinol intolerance or refractoriness, and serum uric acid concentration of 8.0 mg/dL or greater. A total of 225 patients participated: 109 in trial C0405 and 116 in trial C0406. INTERVENTION: Twelve biweekly intravenous infusions containing either pegloticase 8 mg at each infusion (biweekly treatment group), pegloticase alternating with placebo at successive infusions (monthly treatment group), or placebo (placebo group). MAIN OUTCOME MEASURE: Primary end point was plasma uric acid levels of less than 6.0 mg/dL in months 3 and 6. RESULTS: In trial C0405 the primary end point was reached in 20 of 43 patients in the biweekly group (47%; 95% CI, 31%-62%), 8 of 41 patients in the monthly group (20%; 95% CI, 9%-35%), and in 0 patients treated with placebo (0/20; 95% CI, 0%-17%; P < .001 and <.04 for comparisons between biweekly and monthly groups vs placebo, respectively). Among patients treated with pegloticase in trial C0406, 16 of 42 in the biweekly group (38%; 95% CI, 24%-54%) and 21 of 43 in the monthly group (49%; 95% CI, 33%-65%) achieved the primary end point; no placebo-treated patients reached the primary end point (0/23; 95% CI, 0%-15%; P = .001 and < .001, respectively). When data in the 2 trials were pooled, the primary end point was achieved in 36 of 85 patients in the biweekly group (42%; 95% CI, 32%-54%), 29 of 84 patients in the monthly group (35%; 95% CI, 24%-46%), and 0 of 43 patients in the placebo group (0%; 95% CI, 0%-8%; P < .001 for each comparison). Seven deaths (4 in patients receiving pegloticase and 3 in the placebo group) occurred between randomization and closure of the study database (February 15, 2008). CONCLUSION: Among patients with chronic gout, elevated serum uric acid level, and allopurinol intolerance or refractoriness, the use of pegloticase 8 mg either every 2 weeks or every 4 weeks for 6 months resulted in lower uric acid levels compared with placebo. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00325195.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
SF-36 health survey: Manual and interpretation guide
Ware, J. (2003) · Medical Entomology and Zoology · Cited by 11,424
Lawrence, R. C., Felson, D. T., Helmick, C. G., Arnold, L. M., Choi, H., Deyo, R. A., Gabriel, S., Hirsch, R., Hochberg, M. C., Hunder, G. G., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23176 · Cited by 5,499
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Zhang, W., Doherty, M., Bardin, T., Pascual, E., Barskova, V, Conaghan, P., Gerster, J., Jacobs, J., Leeb, B., Lioté, F., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.055269 · Cited by 1,407
Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout
Becker, M. A., Schumacher, H. R., Wortmann, R. L., MacDonald, P. A., Eustace, D., Palo, W. A., Streit, J., & Joseph-Ridge, N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050373 · Cited by 1,357
Self-citationBruce, B., & Fries, J. F. (2003) · PubMed · Cited by 753
Sampson, H. A., Muñoz-Furlong, A., Campbell, R. L., Adkinson, N. F., Allan Bock, S., Branum, A., Brown, S. G. A., Camargo, C. A., Cydulka, R., Galli, S. J., et al. (2006) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2006.01.018 · Cited by 748
Independent Impact of Gout on Mortality and Risk for Coronary Heart Disease
Choi, H. K., & Curhan, G. (2007) · Circulation · doi:10.1161/circulationaha.107.703389 · Cited by 666
Schumacher, H. R., Becker, M. A., Wortmann, R. L., MacDonald, P. A., Hunt, B., Streit, J., Lademacher, C., & Joseph‐Ridge, N. (2008) · Arthritis Care & Research · doi:10.1002/art.24209 · Cited by 638
Self-citationMire-Sluis, A. R., Barrett, Y. C., Devanarayan, V., Koren, E., Liu, H., Maia, M., Parish, T., Scott, G., Shankar, G., Shores, E., et al. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.06.002 · Cited by 624
Two independent mutational events in the loss of urate oxidase during hominoid evolution
Wu, X., Muzny, D. M., Chi Lee, C., & Thomas Caskey, C. (1992) · Journal of Molecular Evolution · doi:10.1007/bf00163854 · Cited by 535
Kosinski, M., Zhao, S. Z., Dedhiya, S., Osterhaus, J. T., & Ware, J. E. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200007)43:7<1478::aid-anr10>3.0.co;2-m · Cited by 505
(1993) · PubMed · Cited by 469
Terkeltaub, R. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmcp030733 · Cited by 456
Gout and the risk of acute myocardial infarction
Krishnan, E., Baker, J. F., Furst, D. E., & Schumacher, H. R. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22014 · Cited by 430
Sarawate, C. A., Brewer, K. K., Yang, W., Patel, P. A., Schumacher, H. R., Saag, K. G., & Bakst, A. W. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.7.925 · Cited by 292
PEG-uricase in the management of treatment-resistant gout and hyperuricemia
Sherman, M. R., Saifer, M. G. P., & Perez-Ruiz, F. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.06.011 · Cited by 291
Crowther, J. R. (2003) · ELISA · doi:10.1385/0-89603-279-5:1 · Cited by 281
Perez-Ruiz, F., Alonso-Ruiz, A., Calabozo, M., Herrero-Beites, A., García-Erauskin, G., & Ruiz-Lucea, E. (1998) · Annals of the Rheumatic Diseases · doi:10.1136/ard.57.9.545 · Cited by 257
Singh, J. A., & Strand, V (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.081604 · Cited by 226
Sundy, J. S., Ganson, N. J., Kelly, S. J., Scarlett, E. L., Rehrig, C. D., Huang, W., & Hershfield, M. S. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22403 · Cited by 221
Quality of Life and Disability in Patients with Treatment-Failure Gout
BECKER, M. A., SCHUMACHER, H. R., BENJAMIN, K. L., GOREVIC, P., GREENWALD, M., FESSEL, J., EDWARDS, L., KAWATA, A. K., FRANK, L., WALTRIP, R., et al. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.071229 · Cited by 187
Sundy, J. S., Becker, M. A., Baraf, H. S. B., Barkhuizen, A., Moreland, L. W., Huang, W., Waltrip, R. W., Maroli, A. N., Horowitz, Z., & Pegloticase Phase 2 Study Investigators (2008) · Arthritis & Rheumatism · doi:10.1002/art.23810 · Cited by 181
White, W. B., Faich, G., Borer, J. S., & Makuch, R. W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00659-3 · Cited by 174
Hyperuricemia and Associated Diseases
Becker, M. A., & Jolly, M. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2006.02.005 · Cited by 162
An Overview of Practical Approaches for Handling Missing Data in Clinical Trials
DeSouza, C., Legedza, A., & Sankoh, A. J. (2009) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400903242795 · Cited by 150
Hershfield, M. S., Roberts, L. J., Ganson, N. J., Kelly, S. J., Santisteban, I., Scarlett, E., Jaggers, D., & Sundy, J. S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001072107 · Cited by 144
Patient-reported outcomes and their role in the assessment of rheumatoid arthritis
Lubeck, D. P. (2004) · PharmacoEconomics · doi:10.2165/00019053-200422001-00004 · Cited by 123
Validation of the Health Assessment Questionnaire disability index in patients with gout
Hernández, E. A., Peláez-Ballestas, I. D. P., Vázquez‐Mellado, J., Terán‐Estrada, L., Bernard‐Medina, A. G., Espinoza, J., Aceves‐Ávila, F. J., Goycochea-Robles, M. V., Garza, M., Ventura, L., et al. (2008) · Arthritis Care & Research · doi:10.1002/art.23575 · Cited by 72
Treatment‐failure gout: A moving target
Edwards, N. L. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23803 · Cited by 57
Epidemiology of Crystal Arthropathy
Choi, H. K. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2006.03.002 · Cited by 35
Taylor, W. J., Colvine, K., Gregory, K., Collis, J. M., McQueen, F. M., & Dalbeth, N. (2008) · PubMed · Cited by 33
Singh, J. A., Yang, S., Strand, V., Simon, L. S., Forsythe, A., Hamburger, S. A., & Chen, L. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.144022 · Cited by 29
Symposium on the Definition and Management of Anaphylaxis
Koscove, E. M. (2006) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2006.06.052 · Cited by 19
Ali, S., & Lally, E. V. (2009) · PubMed · Cited by 11
(2001) · doi:10.1002/1529-0131(200108)45:4<384::aid-art352>3.0.co;2-0
Cited by
2016 updated EULAR evidence-based recommendations for the management of gout
Richette, P., Doherty, M., Pascual, E., Barskova, V, Becce, F., Castañeda-Sanabria, J., Coyfish, M., Guillo, S., Jansen, T. L., Janssens, H., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209707 · Cited by 1,681
Khanna, D., Fitzgerald, J. D., Khanna, P. P., Bae, S., Singh, M. K., Neogi, T., Pillinger, M. H., Merill, J., Lee, S., Prakash, S., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21772 · Cited by 1,536
Dalbeth, N., Gosling, A. L., Gaffo, A., & Abhishek, A. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00569-9 · Cited by 1,338
Dalbeth, N., Merriman, T. R., & Stamp, L. K. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00346-9 · Cited by 1,087
2020 American College of Rheumatology Guideline for the Management of Gout
FitzGerald, J. D., Dalbeth, N., Mikuls, T., Brignardello‐Petersen, R., Guyatt, G., Abeles, A. M., Gelber, A. C., Harrold, L. R., Khanna, D., King, C., et al. (2020) · Arthritis Care & Research · doi:10.1002/acr.24180 · Cited by 983
Metadata
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2011-08-17
- Volume
- 306
- Issue
- 7
- Pages
- 711
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1561987315
- Cited by
- 523
- References
- 38
- FWCI
- 29.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.